Treatment-Resistant Depression Algorithms: Where Ketamine Fits

Introduction: Defining Treatment Resistance in Depression

Treatment-resistant depression (TRD) -- broadly defined as major depressive disorder that fails to respond adequately to two or more antidepressant trials of adequate dose and duration -- affects approximately 30% of patients with major depression and represents a disproportionate share of depression-related disability, healthcare utilization, and mortality (Rush et al., 2006). The positioning of ketamine within treatment-resistant depression algorithms has become a topic of considerable clinical importance following the accumulation of robust efficacy data and the regulatory approval of intranasal esketamine (Spravato) for this indication. Understanding where ketamine fits within the stepwise treatment pathway requires appreciation of TRD staging systems, evidence hierarchies for sequential interventions, and the practical considerations that govern clinical decision-making.

The evolution of TRD treatment algorithms from exclusively monoaminergic strategies to the inclusion of glutamatergic interventions represents a paradigm shift in depression pharmacotherapy. For decades, treatment algorithms followed a predictable sequence: first-line SSRI, second-line SNRI or switch, augmentation with lithium or atypical antipsychotic, and eventual consideration of electroconvulsive therapy (ECT) for the most refractory cases. Ketamine's arrival has disrupted this linear progression, introducing a mechanistically distinct option that can be deployed at various points in the treatment sequence. For an overview of ketamine's glutamatergic mechanism, see the dedicated resource.

Staging Models for Treatment-Resistant Depression

The Thase-Rush Staging Model

The Thase-Rush staging model, first proposed in 1997 and subsequently refined, provides a framework for classifying TRD severity based on the number and nature of failed treatment trials:

• Stage I: Failure of one adequate trial of a major antidepressant class
• Stage II: Failure of two adequate trials of different antidepressant classes
• Stage III: Stage II plus failure of a tricyclic antidepressant trial
• Stage IV: Stage III plus failure of a monoamine oxidase inhibitor trial
• Stage V: Stage IV plus failure of electroconvulsive therapy

This model, while widely referenced, has limitations including the absence of augmentation strategies from the staging criteria and the assumption that TCA and MAOI trials should precede more invasive interventions (Thase and Rush, 1997). Contemporary treatment patterns often bypass TCAs and MAOIs -- due to side effect burden and safety concerns -- proceeding instead to augmentation strategies, ketamine, or neuromodulation.

The Massachusetts General Hospital Staging Model

The MGH staging method offers a more quantitative approach, assigning resistance scores based on the number of failed trials, optimization of dose and duration, and incorporation of augmentation and combination strategies (Fava, 2003). This model provides a continuous measure of treatment resistance that has been validated against clinical outcomes and is used in research settings to characterize study populations. Higher MGH staging scores predict lower response rates to subsequent interventions and poorer overall prognosis.

The Conventional Treatment Algorithm

Steps 1-2: First-Line Antidepressant Therapy

Current evidence-based guidelines uniformly recommend SSRIs or SNRIs as first-line pharmacotherapy for major depression. The STAR*D trial -- the largest prospective study of sequential depression treatments -- demonstrated that approximately 37% of patients achieve remission with first-line citalopram, with an additional 31% remitting with a second antidepressant trial (Rush et al., 2006). Adequate trial duration is defined as 4-8 weeks at therapeutic dose, though some patients require 10-12 weeks for full response assessment.

Step 3: Augmentation Strategies

For patients failing two antidepressant trials, augmentation with a second agent represents the most common next step. Evidence-supported augmentation strategies include:

• Lithium augmentation: The best-studied augmentation strategy, with meta-analytic evidence supporting efficacy (response rate approximately 40-50%) but limited by tolerability concerns including thyroid and renal effects (Nelson et al., 2014)
• Atypical antipsychotic augmentation: Aripiprazole, quetiapine, and olanzapine-fluoxetine combination carry regulatory approval for adjunctive depression treatment, with effect sizes comparable to lithium but distinct metabolic side effect profiles (Nelson and Papakostas, 2009)
• Thyroid hormone (T3) augmentation: Modest evidence supporting addition of liothyronine 25-50 mcg daily, with favorable tolerability
• Combination antidepressants: Mirtazapine added to an SSRI/SNRI or bupropion combination strategies

Step 4: Neuromodulation

Electroconvulsive therapy remains the most effective treatment for severe, refractory depression, with response rates of 50-70%. For a comparison of cost-effectiveness across these interventions, see the dedicated analysis. even in highly treatment-resistant populations (UK ECT Review Group, 2003). However, cognitive side effects (particularly retrograde amnesia), logistical requirements (general anesthesia, multiple sessions), and patient preference barriers limit its utilization. Repetitive transcranial magnetic stimulation (rTMS) offers a non-invasive alternative with modest effect sizes in TRD (approximately 25-35% response rates) and minimal cognitive effects (George et al., 2010).

Where Ketamine Enters the Algorithm

Current Guideline Positioning

Major clinical practice guidelines have begun incorporating ketamine and esketamine into TRD algorithms, though positioning varies:

• American Psychiatric Association (APA) Guidelines: The 2023 practice guideline update acknowledges esketamine as an FDA-approved option for TRD, positioning it alongside established augmentation strategies for patients who have failed at least two adequate antidepressant trials (APA, 2023).
• CANMAT Guidelines: The Canadian Network for Mood and Anxiety Treatments assigns Level 1 evidence to intranasal esketamine for TRD and Level 2 evidence to intravenous racemic ketamine, positioning both as third-line options after failure of first-line antidepressants and augmentation strategies (Kennedy et al., 2016, updated 2022).
• NICE Guidelines: The UK National Institute for Health and Care Excellence has issued technology appraisal guidance recommending esketamine as an option for TRD in combination with an SSRI or SNRI, specifically after failure of at least two antidepressant treatments.
• VA/DoD Clinical Practice Guidelines: Position ketamine as a consideration for TRD after failure of evidence-based pharmacotherapy and psychotherapy, with emphasis on monitoring requirements and supervised administration.

Evidence-Based Positioning Rationale

The positioning of ketamine as a third-line or later option reflects several considerations:

1. Evidence hierarchy: While ketamine's efficacy data are robust for short-term response, long-term durability data are less extensive than for first-line agents and established augmentation strategies.
2. Practical burden: Supervised administration requirements, monitoring protocols, and session frequency represent greater logistical demands than oral pharmacotherapy.
3. Safety profile: The dissociative effects, abuse potential, and long-term safety uncertainties of ketamine are viewed as acceptable after failed trials of better-characterized agents but premature as an early-line intervention.
4. Cost considerations: The per-session cost of ketamine treatment exceeds that of oral medications, though comparative cost-effectiveness analyses suggest favorable economic profiles in the TRD population (Ross and Soeteman, 2020).

Ketamine Versus Existing TRD Interventions

Comparison with Augmentation Strategies

In head-to-head comparisons, ketamine appears to offer several advantages over conventional augmentation:

• Speed of onset: Ketamine produces antidepressant response within hours versus 2-6 weeks for lithium and atypical antipsychotic augmentation
• Magnitude of effect: Response rates of 50-70% at 24 hours post-infusion compare favorably with 30-50% response rates for augmentation strategies
• Anti-suicidal effects: Rapid reduction of suicidal ideation represents a unique and clinically critical advantage not demonstrated by augmentation agents (Wilkinson et al., 2018)

Disadvantages include the transient nature of single-infusion response, the requirement for clinic-based administration, and the less characterized long-term safety profile.

Comparison with Electroconvulsive Therapy

The comparison between ketamine and ECT is particularly clinically relevant, as both are considered options for severe, refractory depression. Anand and colleagues (2023), in a large non-inferiority trial published in The New England Journal of Medicine, compared intravenous ketamine (twice-weekly for three weeks) with ECT (thrice-weekly for three weeks) in non-psychotic TRD. Ketamine was non-inferior to ECT in antidepressant efficacy, with response rates of 55% (ketamine) versus 41% (ECT) -- actually favoring ketamine numerically. Ketamine was associated with fewer cognitive side effects and was preferred by patients, though ECT may retain advantages in psychotic depression and catatonia.

This trial has significantly influenced the positioning of ketamine relative to ECT in treatment algorithms, with some experts now arguing that ketamine should be tried before ECT given its comparable efficacy, superior cognitive safety, and patient preference advantages (McIntyre et al., 2021).

Proposed Updated Algorithm

A Revised Stepwise Approach

Based on current evidence, an updated TRD algorithm might be structured as follows:

Step 1: First-line SSRI or SNRI (4-8 weeks)

Step 2: Switch to different class antidepressant or augmentation with aripiprazole, lithium, or quetiapine (4-8 weeks)

Step 3A (non-urgent): Trial of additional augmentation strategy or combination antidepressant therapy

Step 3B (urgent -- active suicidal ideation or severe functional impairment): Ketamine/esketamine as bridge therapy, concurrent with optimization of oral pharmacotherapy

Step 4: Ketamine/esketamine series if not previously tried; rTMS for patients preferring non-pharmacological approaches

Step 5: Electroconvulsive therapy for non-responders to prior steps, psychotic depression, or catatonia

Step 6: Vagus nerve stimulation, investigational treatments, or combination neuromodulation strategies

Emergency and Acute Settings

In psychiatric emergencies involving acute suicidal ideation with imminent risk, ketamine's unique rapid-onset anti-suicidal properties may justify earlier deployment -- potentially as a first-line intervention concurrent with standard crisis management. Emerging evidence supports this use, though formal guidelines for emergency ketamine use in suicidality are still in development.

Barriers to Algorithm Implementation

Access and Infrastructure

Implementation of ketamine into TRD algorithms faces practical barriers including the need for clinic-based administration with monitoring infrastructure, limited availability of certified esketamine treatment centers (particularly in rural areas), and workforce requirements for supervised sessions. These infrastructure demands may create inequitable access patterns that disproportionately affect underserved populations.

Insurance and Reimbursement

While esketamine (Spravato) has a defined reimbursement pathway, off-label IV racemic ketamine faces variable insurance coverage. The cost differential between FDA-approved esketamine and generic racemic ketamine creates tension between regulatory certainty and economic efficiency that has not been resolved through consensus guidelines.

Conclusion

The integration of ketamine into treatment-resistant depression algorithms represents a significant advance in the management of refractory mood disorders. Current evidence supports positioning ketamine as a third-line intervention for patients who have failed adequate trials of first-line antidepressants and augmentation strategies, with earlier deployment justified in clinical emergencies involving acute suicidal ideation. The landmark non-inferiority trial demonstrating comparable efficacy to ECT with superior cognitive safety has further strengthened ketamine's position in the treatment hierarchy. As long-term efficacy and safety data accumulate, the precise positioning of ketamine within TRD algorithms will continue to evolve toward evidence-based consensus.

References

• NICE: National Institute for Health and Care Excellence — UK evidence-based clinical guidelines for depression treatment including treatment-resistant algorithms
• NIMH: Depression Overview — National Institute of Mental Health information on depression treatment staging and research
• MedlinePlus: Esketamine Nasal Spray Drug Information — National Library of Medicine information on FDA-approved esketamine for treatment-resistant depression
• PubMed: Ketamine for Treatment of Major Depressive Episodes: Systematic Review and Meta-Analysis — Meta-analysis supporting ketamine's positioning in TRD treatment pathways